Annovis

Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults See more here

Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study See more here

Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases See more here

Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease After COVID-Related Delay See more here

Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award See more here

Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal transport, the information…

Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial See more here

Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients See more here

Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study See more here

Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19 See more here